Precision Optics Corporation Inc

Precision Optics Corporation Inc(POCI)股票分析

$4.400

-0.030 (-0.68%)收盤時

Loading chart…
High
4.535
Open
4.390
VWAP
4.41
Vol
43.15K
Mkt Cap
35.15M
Low
4.300
Amount
190.34K
EV/EBITDA, TTM
3,328.28

Precision Optics Corporation, Inc. is a developer and manufacturer of optical instruments. The Company’s segments include medical devices and advanced defense/aerospace products. Its optical and imaging technology, custom designs, manufacturing capabilities, and engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using complementary metal-oxide-semiconductor (CMOS) sensor technology, some designed and manufactured for single-use, as well as other custom imaging and illumination products for our customers’ use in minimally invasive surgical procedures. It designs and manufactures precision endoscopes and microprecision lenses, assemblies and complete medical devices to meet the surgical community’s demand for imaging systems for minimally invasive surgery. Its technologies serve defense / aerospace markets, including applications supporting satellite network communications.

www.poci.com

AI analysis of Precision Optics Corporation Inc (POCI)

buy

Precision Optics Corporation Inc (POCI) is a good buy right now due to its recent strong revenue growth of 107.1% year-over-year, with Q3 revenue reaching $8.7 million, and an upward revision of fiscal year 2026 revenue guidance to $29-$31 million. The current price of $4.40 is above the Fibonacci support level of $4.204, indicating potential for upward movement. However, the main risk is the negative net income of -$108,283 in Q3 2026, which highlights ongoing profitability challenges.

估值指標

The current forward P/E ratio for Precision Optics Corporation Inc (POCI) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued
5Y Average P/E
0.00
Current P/E
0.00
高估
0.00
低估
0.00

Forward EV/EBITDA

Strongly Overvalued
5Y Average EV/EBITDA
252.75
Current EV/EBITDA
3328.28
高估
1199.40
低估
-693.89

Forward P/S

Strongly Overvalued
5Y Average P/S
0.11
Current P/S
1.40
高估
0.50
低估
-0.29

Alphio AI Price Scenarios for POCI

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%POCI

$4.83

情境價格

B

Base

Base · 50%POCI

$4.56

情境價格

B

Bear

Bear · 25%POCI

$3.87

情境價格

事件時間軸

2026-03-27 (ET)

07:50:00

Lucid Capital Offering Priced Below Last Closing Price of $4.21

2026-03-26 (ET)

16:10:00

Precision Optics Corporation Launches Underwritten Public Offering

2025-11-11 (ET)

09:05:48

Precision Optics reveals partnership for product development

2025-11-07 (ET)

09:01:55

Precision Optics Secures Order for Development of AR Sub-Systems

2025-06-05 (ET)

09:03:32

Precision Optics expands facilities to meet growing backlog

資訊

POCI FAQ — answered by Alphio AI

Precision Optics Corporation, Inc. is a developer and manufacturer of optical instruments. The Company’s segments include medical devices and advanced defense/aerospace products. Its optical and imaging technology, custom designs, manufacturing capabilities, and engineering and development capabilities have generated traditional endoscopes and endocouplers, digital imaging endoscopes using complementary metal-oxide-semiconductor (CMOS) sensor technology, some designed and manufactured for single-use, as well as other custom imaging and illumination products for our customers’ use in minimally invasive surgical procedures. It designs and manufactures precision endoscopes and microprecision lenses, assemblies and complete medical devices to meet the surgical community’s demand for imaging systems for minimally invasive surgery. Its technologies serve defense / aerospace markets, including applications supporting satellite network communications. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Precision Optics Corporation Inc (POCI) is a good buy right now due to its recent strong revenue growth of 107.1% year-over-year, with Q3 revenue reaching $8.7 million, and an upward revision of fiscal year 2026 revenue guidance to $29-$31 million. The current price of $4.40 is above the Fibonacci support level of $4.204, indicating potential for upward movement. However, the main risk is the negative net income of -$108,283 in Q3 2026, which highlights ongoing profitability challenges.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始